Literature DB >> 11354696

Intrathecal chemotherapy with antineoplastic agents in children.

A Ruggiero1, V Conter, M Milani, E Biagi, I Lazzareschi, P Sparano, R Riccardi.   

Abstract

Intrathecal chemotherapy with antineoplastic agents is mainly utilised in children with leukaemia and lymphoma, and in selected brain tumours. In these diseases, intrathecal use is restricted to methotrexate (MTX), cytosine arabinoside (Ara-C) and corticosteroids. A number of other agents are, at the present time, under evaluation. Intrathecal MTX administered sequentially with systemic high dose MTX infusion prolongs therapeutic cerebral spinal fluid (CSF) levels of the drug. Prolonged therapeutic CSF levels can also be achieved by giving repeated small intrathecal doses of MTX over an extended period in selected patients, with an implanted Ommaya reservoir. In the CSF, the metabolic inactivation of Ara-C is significantly lower than in plasma with a CSF clearance similar to the rate of CSF bulk flow. A slow-release formulation of Ara-C may be given intrathecally, resulting in a prolonged cytotoxic concentration in the CSF. CNS relapse and neurotoxicity in patients with acute lymphoblastic leukaemia, especially younger children, may be reduced by using age-related dosing of intrathecal MTX and Ara-C. Hydrocortisone is used in combination with MTX and Ara-C for so-called 'triple intrathecal chemotherapy' in the treatment of meningeal leukaemia. Intrathecal thiotepa does not appear to be advantageous over systemic administration in patients with brain and meningeal leukaemia. Monoclonal antibodies, reactive with tumour-associated antigens, can be used as delivery systems for chemotherapeutic agents and radionuclides. However, the development of this new approach is currently under evaluation in larger clinical studies. Neurological adverse effects may be expected with intrathecal chemotherapy and are increased by high dose systemic therapy, concomitant cranial radiotherapy or meningeal infiltration by neoplastic cells. Inadvertant intrathecal administration of antineoplastic agents that are indicated for systemic administration only, is dangerous and may result in a fatal outcome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11354696     DOI: 10.2165/00128072-200103040-00001

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  60 in total

1.  Intrathecal depot cytarabine therapy: a welcome addition to a limited armamentarium.

Authors:  W A Bleyer
Journal:  Clin Cancer Res       Date:  1999-11       Impact factor: 12.531

2.  Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia.

Authors:  R J Aur; J Simone; H O Hustu; T Walters; L Borella; C Pratt; D Pinkel
Journal:  Blood       Date:  1971-03       Impact factor: 22.113

3.  The influence of previous lumbar puncture and pneumoencephalography on the incidence of unsuccessful radioisotope cisternography.

Authors:  S M Larson; G L Schall; G Di Chiro
Journal:  J Nucl Med       Date:  1971-08       Impact factor: 10.057

4.  Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity.

Authors:  G W Camiener; C G Smith
Journal:  Biochem Pharmacol       Date:  1965-10       Impact factor: 5.858

Review 5.  Morphology of blood-brain interfaces.

Authors:  M W Brightman
Journal:  Exp Eye Res       Date:  1977       Impact factor: 3.467

6.  Intrathecal 6-mercaptopurine: preclinical pharmacology, phase I/II trial, and pharmacokinetic study.

Authors:  P C Adamson; F M Balis; C A Arndt; J S Holcenberg; P K Narang; R F Murphy; A J Gillespie; D G Poplack
Journal:  Cancer Res       Date:  1991-11-15       Impact factor: 12.701

7.  Successful treatment of intrathecal methotrexate overdose by using ventriculolumbar perfusion and intrathecal instillation of carboxypeptidase G2.

Authors:  A S O'Marcaigh; C M Johnson; W A Smithson; M C Patterson; B C Widemann; P C Adamson; M J McManus
Journal:  Mayo Clin Proc       Date:  1996-02       Impact factor: 7.616

8.  Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.

Authors:  M T Brown; R E Coleman; A H Friedman; H S Friedman; R E McLendon; R Reiman; G J Felsberg; R D Tien; S H Bigner; M R Zalutsky; X G Zhao; C J Wikstrand; C N Pegram; J E Herndon; N A Vick; N Paleologos; R K Fredericks; S C Schold; D D Bigner
Journal:  Clin Cancer Res       Date:  1996-06       Impact factor: 12.531

9.  Change in transfer rate of methotrexate from spinal fluid to plasma during intrathecal therapy in children and adults.

Authors:  J Lankelma; R J Lippens; A Drenthe-Schonk; E F Termond; E van der Kleijn
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

10.  Central nervous system pharmacokinetics of high-dose cytosine arabinoside.

Authors:  J A Lopez; E Nassif; P Vannicola; J G Krikorian; R P Agarwal
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

View more
  11 in total

1.  Case files of the New York City Poison Control Center: antidotal strategies for the management of methotrexate toxicity.

Authors:  Silas W Smith; Lewis S Nelson
Journal:  J Med Toxicol       Date:  2008-06

2.  Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.

Authors:  Yousif Matloub; Susan Lindemulder; Paul S Gaynon; Harland Sather; Mei La; Emmett Broxson; Rochelle Yanofsky; Raymond Hutchinson; Nyla A Heerema; James Nachman; Marilyn Blake; Linda M Wells; April D Sorrell; Margaret Masterson; John F Kelleher; Linda C Stork
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

Review 3.  The glymphatic system: implications for drugs for central nervous system diseases.

Authors:  Terhi J Lohela; Tuomas O Lilius; Maiken Nedergaard
Journal:  Nat Rev Drug Discov       Date:  2022-08-10       Impact factor: 112.288

4.  Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors.

Authors:  Bernard L Marini; Lydia L Benitez; Andrew H Zureick; Ralph Salloum; Angela C Gauthier; Julia Brown; Yi-Mi Wu; Dan R Robinson; Chandan Kumar; Robert Lonigro; Pankaj Vats; Xuhong Cao; Katayoon Kasaian; Bailey Anderson; Brendan Mullan; Benjamin Chandler; Joseph R Linzey; Sandra I Camelo-Piragua; Sriram Venneti; Paul E McKeever; Kathryn A McFadden; Andrew P Lieberman; Noah Brown; Lina Shao; Marcia A S Leonard; Larry Junck; Erin McKean; Cormac O Maher; Hugh J L Garton; Karin M Muraszko; Shawn Hervey-Jumper; Jean M Mulcahy-Levy; Adam Green; Lindsey M Hoffman; Katie Dorris; Nicholas A Vitanza; Joanne Wang; Jonathan Schwartz; Rishi Lulla; Natasha Pillay Smiley; Miriam Bornhorst; Daphne A Haas-Kogan; Patricia L Robertson; Arul M Chinnaiyan; Rajen Mody; Carl Koschmann
Journal:  Transl Res       Date:  2017-08-10       Impact factor: 7.012

5.  Leptin consumption in the inflamed joints of patients with rheumatoid arthritis.

Authors:  M Bokarewa; D Bokarew; O Hultgren; A Tarkowski
Journal:  Ann Rheum Dis       Date:  2003-10       Impact factor: 19.103

Review 6.  Neurotoxicity of chemotherapeutic and biologic agents in children with cancer.

Authors:  Kevin C De Braganca; Roger J Packer
Journal:  Curr Neurol Neurosci Rep       Date:  2008-03       Impact factor: 5.081

7.  Intrathecal chemotherapy for refractory disseminated medulloblastoma.

Authors:  Junichi Yoshimura; Kenichi Nishiyama; Hiroshi Mori; Hideaki Takahashi; Yukihiko Fujii
Journal:  Childs Nerv Syst       Date:  2007-12-05       Impact factor: 1.475

8.  Detection of lower levels of SNAP25 using multiple microarray systems and its functional significance in medulloblastoma.

Authors:  Chi-Jung Huang; Chia-Long Lee; Chih-Yi Liu; Shih-Hung Huang; Jia-Woei Hou; Yi-Hou Chen; Chih-Cheng Chien; Chih-Ming Ho; Wen-Cheng Lo; Kun-Long Hung
Journal:  Int J Mol Med       Date:  2017-03-20       Impact factor: 4.101

Review 9.  How to Treat Involvement of the Central Nervous System in Hemophagocytic Lymphohistiocytosis?

Authors:  AnnaCarin Horne; Ronny Wickström; Michael B Jordan; E Ann Yeh; Ahmed Naqvi; Jan-Inge Henter; Gritta Janka
Journal:  Curr Treat Options Neurol       Date:  2017-01       Impact factor: 3.598

Review 10.  Improving the Brain Delivery of Chemotherapeutic Drugs in Childhood Brain Tumors.

Authors:  Silvia Triarico; Palma Maurizi; Stefano Mastrangelo; Giorgio Attinà; Michele Antonio Capozza; Antonio Ruggiero
Journal:  Cancers (Basel)       Date:  2019-06-13       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.